Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

613.P1.41 Acute Myeloid Leukemia - Biology and Pathophysiology Poster I

Saturday, December 6, 2008: 5:30 PM-7:30 PM
Hall A (Moscone Center)
Superiority of Rasburicase Versus Allopurinol on Serum Uric Acid Control in Adult Patients with Hematological Malignancies at Risk of Developing Tumor Lysis Syndrome : Results of a Randomized Comparative Phase III Study

Jorge Cortes, MD1, Karen Seiter, MD2, Richard Thomas Maziarz, MD3, Meir Wetzler, MD4, Michael Craig, MD5*, Jeffrey Matous6, Selina Luger, MD7, Bimalangshu Dey, MD8, Gary J. Schiller, MD, FACP9, Dat Pham, MD10, Camille N. Abboud, MD, FACP11, Muthuswamy Krishnamurthy, MD12*, Archie Brown Jr., MD13 and Joseph O. Moore, MD14*

1M.D. Anderson Cancer Center, Houston, TX
2New York Medical College, Valhalla, NY
3OR Health Sciences Univ., Portland, OR
4Roswell Park Cancer Inst., Buffalo, NY
5WVU, Morgantown, WV
6Rocky Mountain Cancer Center, Denver, CO
7Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
8Mass General Hospital, Boston, MA
9UCLA School of Medicine, Los Angeles, CA
10UF Shands Jacksonville, Jacksonville, FL
11Bone Marrow Transplant, Washington Univresity, Saint Louis, MO
12New York Methodist Hospital, Brooklyn, NY
13Ochsner Clinic Foundation, New Orleans, LA
14Duke Medical Center, Durham, NC

Pediatric Patients with Extramedullary Leukemia Involving the Central Nervous System Have a Superior Outcome

Donna Johnston, MD, FRCPC1, Todd Alonzo, PhD2, Robert Gerbing3*, Beverly Lange, MD4 and William G. Woods, MD5

1Children's Hospital of Eastern Ontario, Ottawa, ON, Canada
2Keck School of Med., Univ. of Southern California, Arcadia, CA
3Children's Oncology Group, Arcadia, CA
4Oncology, Children's Hosp. of Philadelphia, Philadelphia, PA
5Emory University, Atlanta, GA

Development of a Prognostic Scoring System for Secondary Acute Myeloid Leukemia (sAML) Arising from Myelodysplastic Syndromes (MDS), Myeloproliferative Disorders (MPD), or Therapy-Related AML (t-AML)

Sanjay R. Mohan, MD1*, Paul Elson, ScD1*, Cristina Rodriguez, MD1*, Rachid Baz, MD2*, Matt Kalaycio, MD1*, Ronald Sobecks, MD1*, Anjali Advani, MD1, Ed Copelan, MD1*, Lukasz P. Gondek, MD1*, Jaroslaw P. Maciejewski, MD, PhD1 and Mikkael A. Sekeres, MD, MS1

1Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Moffitt Cancer Center, Tampa, FL

Clinical Characterization of Acute Myeloid Leukemia with Myelodysplasia-Related Changes as Defined by the 2008 WHO Classification System

Olga K Weinberg, MD1*, Mahesh Seetharam, MD2*, Li Ren, MS3*, Lisa Ma, MS1*, Katie Seo, MS1*, Jason D. Merker, MD, PhD1*, Jason R. Gotlib, MD2*, James L. Zehnder, MD2 and Daniel A. Arber, MD1

1Pathology, Stanford Univ. Medical Center, Stanford, CA
2Hematology, Stanford Univ. Medical Center, Stanford, CA
3Center for Clinical Investigation, Department of Medicine, Stanford Univ. Medical Center, Stanford, CA

GATA1 Mutations in Transient Leukemia and Myeloid Leukemia in "Down" Syndrome

Katarina Reinhardt, PhD1*, Katarina Boehmer1*, Jan-Henning Klusmann, MD1*, Manuela Germeshausen, PhD1, Annette Sander, MD1*, Christine von Neuhoff, MD1*, Jan Stary, MD, PhD2*, Heribert Jürgens, MD, PhD3*, Arnulf Pekrun, MD, PhD4*, Axel Sauerbrey, MD, PhD5*, Charlotte M Niemeyer, MD, PhD6, Gudrun Fleischhack, MD, PhD7*, Ursula Creutzig, MD, PhD3 and Dirk Reinhardt, MD, PhD1

1Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany
2Dept of Pediatric Hematology and Oncology, 2nd Medical School, Charles University, University Hospital Motol, Prague, Czech Republic
3Pediatric Hematology and Oncology, University Childrens Hospital, Münster, Germany
4Pediatric Hematology and Oncology, Prof. Hess Kinderklinik, Bremen, Germany
5Pediatrics, HELIOS Kliniken GmbH, Erfurt, Germany
6Universitaets-Kinderklinik, Freiburg, Germany
7Pediatric Hematology and Oncology, University Childrens Hospital Bonn, Bonn, Germany

RUNX1 Mutations in Normal Karyotype MDS Cooperate with Class I Mutations in the Progression to S-AML Following MDS

Frank Dicker, PhD, Claudia Haferlach, MD, Wolfgang Kern, MD, Torsten Haferlach, MD and Susanne Schnittger, PhD

MLL Munich Leukemia Laboratory GmbH, Munich, Germany

Acute Erythroleukemia: An Analysis of 108 Patients Treated with Cytarabine-Containing Regimens at the M.D. Anderson Cancer Center

Fabio P.S. Santos, MD1, Stefan Faderl, MD1*, Guillermo Garcia-Manero, MD1*, Charles A. Koller, MD1*, Miloslav Beran, MD, PhD1*, Gautam Borthakur, MD1*, Carlos Bueso-Ramos, MD, PhD2*, Michael Keating, MB, BS1*, Jorge Cortes, MD1*, Hagop M. Kantarjian, MD1* and Farhad Ravandi, MD1*

1Leukemia Department, University of Texas - M.D. Anderson Cancer Center, Houston, TX
2Department of Hematopathology, University of Texas - M.D. Anderson Cancer Center, Houston, TX

Expression of 67-Kda Laminin Receptor (67LR) Relates to the Aggressiveness and Poor Prognosis of AML: Modulation of the Expression of GM-CSF Receptor by 67LR

Koji Ando, MD1*, Yasushi Miyazaki1, Daisuke Imanishi2*, Masako Iwanaga1, Hideki Tsushima1*, Jun Taguchi1*, Takuya Fukushima1*, Shinichiro Yoshida1*, Tomoko Hata1* and Masao Tomonaga, MD, PhD2

1Hematology and Molecular Medicine, Nagasaki University, Nagasaki, Japan
2Hematology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan

NDRG1 Expression Is Inhibited in AML and Its Knockdown Attenuates Neutrophil Differentiation

Mario P. Tschan, PhD1, Deborah Shan1*, Judith Laedrach1*, Marianne Eyholzer1*, Elisabeth Oppliger Leibundgut, PhD1*, Gabriela Baerlocher, MD2, Andreas Tobler, MD2, Deborah Stroka, PhD1* and Martin F. Fey, MD3

1Department of Clinical Research, University of Bern, Bern, Switzerland
2Department of Hematology, Inselspital, Bern, Switzerland
3Medical Oncology, Inselspital, Bern, Switzerland

AML1-ETO Collaborates with the Homeobox Gene Meis1 in Inducing Acute Leukemia in the Mouse Bone Marrow Transplantation Model

Vegi M. Naidu, MSc1*, Vijay P.S. Rawat, PhD1*, Christina Schessl, PhD2*, Konstantin Petropoulus, PhD2*, Monica Cusan, Dr2*, Aniruddha J Deshpande, PhD2*, Leticia Quintanilla Martinez, MD3*, Wolfgang Hiddemann, Prof4*, Michaela Feuring Buske, MD1* and Christian Buske, MD2*

1CCG Leukemia, Helmholtz Zentrum muenchen, GSF, Munich, Germany
2CCG Leukemia, Helmholtz Zentrum muenchen, Munich, Germany
3Department of Pathology, GSF, Munich, Germany
4Department of Medicine III, Klinikum Grosshadern, LMU, Munich, Germany

The Re-Activation of FoxO3 Transcription Factor in Acute Myeloid Leukaemia Is Responsible for the Induction of a Quiescent Status of Leukaemic Progenitor Cells

Daniela Cilloni1, Cristina Panuzzo, PhD2*, Francesca Arruga, PhD1*, Francesca Messa, PhD2*, Monica Pradotto, PhD1*, Enrico Bracco, PhD3*, Alessandro Morotti, MD1*, Emanuela Messa1*, Antonia Rotolo4*, Ilaria Iacobucci5*, Chiara Marrè1*, Marisa Pautasso1*, Giovanni Martinelli, MD6* and Giuseppe Saglio1*

1Dept. Of Clinical and Biological Sciences, University of Turin, Turin, Italy
2Department of Clinical and Biological Sciences, University of Turin, Orbassano,Turin, Italy
3Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
4Department of Clinical and Biological Sciences, University of Turin, Orbassano, Turin, Italy
5Seragnoli Institute of Hematology, University of Bologna, Bologna, Italy
6Department of Hematology and Oncological Sciences, University of Bologna, Bologna, Italy

A Protease-Resistant PML-RARα Has Increased Leukemogenic Potential in a Murine Model of Acute Promyelocytic Leukemia (APL)

Geoffrey L. Uy, MD, John S. Welch, MD, PhD, Andrew A. Lane, MD, PhD* and Timothy J. Ley, MD

Division of Oncology, Washington University School of Medicine, Saint Louis, MO

Phosphoinositide 3-Kinase p110δ Is Dispensable for HoxA9/Meis1 and MLL-AF9 Mediated Leukemogenesis

Kenneth Gibbs Jr., BS1* and Garry P. Nolan, PhD2*

1Stanford University School of Medicine, Stanford, CA
2Department of Microbiology and Immunology, Stanford University School of Medicine, Palo Alto, CA

Expression of PML-RARα by the Murine PML Locus Leads to Myeloid Self-Renewal, Clonal Expansion and Morphologic Promyelocytic Leukemia

John S. Welch, MD, PhD1, Wenlin Yuan, PhD2* and Timothy James Ley, MD3

1Division of Oncology, Washington University School of Medicine, Saint Louis, MO
2Genentech, South San Francisco, CA
3Department of Medicine, Washington University School of Medicine, St. Louis, MO

Natural Killer (NK) or NK/T Cell Lineage Large Granular Lymphocytosis Associated with Dasatinib Therapy for Philadelphia Chromosome Positive Leukemia

Dong Hwan Kim, MD, PhD1, Suzanne Kamel-Reid, PhD, FACMG2, Hong Chang, MD3, Robert Sutherland, Ph.D.4*, Chul Won Jung, M.D./Ph.D.1*, Hyeoung Joon Kim, MD5, Je-Jung Lee, MD, PhD6 and Jeffrey H. Lipton, MD, PhD3

1Hematology/Med. Oncology, Samsung Medical Center, Seoul, South Korea
2Applied Molecular Oncology, Ontario Cancer Institute, Toronto, ON, Canada
3Princess Margaret Hospital, Toronto, ON, Canada
4Laboratory Hematology, Princess Margaret Hospital, Toronto, ON, Canada
5Hematology-Oncology, Chonnam National University Hwasun Hospital, Jellanamdo, South Korea
6Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Jellanamdo, South Korea

Protein Synthesis Escapes mTORC1 Control and Constitutes a Promising Therapeutic Target in Acute Myeloid Leukemia

Jerome Tamburini1*, Alexa Samantha Green1*, Valérie Bardet1*, Nicolas Chapuis1*, Lise Willems1*, Sophie Park1*, Madalina Uzunov2*, Norbert Ifrah3*, Francois Dreyfus4*, Patrick Mayeux1*, Catherine Lacombe1 and Didier Bouscary, MD, PhD5*

1Hematology, Institut Cochin, Paris, France
2Service d'Hématologie Clinique, Hôpital Pitié-Salpêtrière, Paris, France
3service Hématologie, CHU Angers,, Angers, France
4Service d'hématologie, Hôpital Cochin, Bobigny, France
5Hematologie, Institut Cochin, Paris, France

mTORC1 Activity Is Independent of PI3K/Akt but Controlled by AMPK in Acute Myeloid Leukemia

Alexa Samantha Green1*, Jerome Tamburini1*, Lise Willems1*, Nicolas Chapuis1*, Sophie Park1*, Valérie Bardet1*, Marc Foretz1*, Benoit Viollet1*, Norbert Ifrah2*, Francois Dreyfus3*, Patrick Mayeux1*, Catherine Lacombe1 and Didier Bouscary, MD, PhD4*

1Hematology, Institut Cochin, Paris, France
2service Hématologie, CHU Angers,, Angers, France
3Service d'hématologie, Hôpital Cochin, Paris, France
4Hematologie, Institut Cochin, Paris, France

Disruption of the NHR4 Domain Structure in AML1-ETO Abrogates Its Interaction with SON and Promotes AML1-ETO-Associated Leukemogenesis

Eun-Young Ahn, PhD1*, Ming Yan, Ph.D.1*, Oxana A Malakhova, M.S.1*, Anita Boyapati, Ph.D.1*, Hans Beier Ommen, M.D.2*, Robert Hines, Ph.D.1*, Peter Hokland, M.D.2* and Dong-Er Zhang, Ph.D.1

1Moores Cancer Center, University of California San Diego, La Jolla, CA
2Department of Hematology, Aarhus University Hospital, Aarhus, Denmark

Autocrine IGF-1/IGF-1R Signaling Is Responsible for PI3K/Akt Constitutive Activation in Acute Myeloid Leukemia

Nicolas Chapuis1*, Jerome Tamburini1*, Pascale Cornillet-Lefebvre2*, Lucile Gillot2*, Valérie Bardet1*, Lise Willems1*, Sophie Park1*, Alexa Samantha Green1*, Norbert Ifrah3, Francois Dreyfus4*, Patrick Mayeux1*, Catherine Lacombe1 and Didier Bouscary1*

1Hematology, Institut Cochin, Paris, France
2CHU Reims, Reims, France
3Service des Maladies du Sang, CHU d'Angers, Angers, France
4Service d'hématologie, Hopital Cochin, Paris, France

CXCR4 Expression and Biological Activity Is Dependent on Oxygen Partial Pressure in Acute Myeloid Leukemia

Michael Fiegl, Ph.D.1*, Ismael J. Samudio, Ph.D.1*, Karen Clise Dwyer, Ph.D.1*, Jared Burks, Ph.D.1*, Herbert Fritsche, Ph.D.2*, Zakar H. Mnjoyan, Ph.D.1* and Michael Andreeff, M.D., Ph.D.1

1Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
2Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Prognostic Implication and Biological Roles of RhoH in Acute Myeloid Leukemia

Akira Katsumi, MD, PhD1*, Toshihiro Iwasaki, MD, PhD1*, Ryohei Tanizaki, MS1*, Akihiro Abe, MD, PhD1, Hitoshi Kiyoi, MD, PhD2 and Tomoki Naoe, MD, PhD1

1Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
2Department of Infectious Diseases, Nagoya University Graduate School of Medicine, Nagoya, Japan

*signifies non-member of ASH